


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A halogenated amino acid analogue ~~for use in diagnosis~~,  
the analogue having the general formula:



wherein:

X is a radioactive halogen;

m is 0 or 1;

n is 0, 1, 2, 3, 4, 5, or 6;

R is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with thioether or ether oxygen atom when n is 0;

and

R is a substituted aromatic or heteroaromatic ring when n is 1, 2, 3, 4, 5 or 6.

2. (Original) The analogue of claim 1, wherein R is methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl or methyl thioethyl.

3. (Original) The analogue of claim 1, wherein R is phenyl, hydroxyphenyl, pyridyl or hydroxypyridyl.

4. (Cancelled).

5. (Original) The analogue of claim 4, wherein the halogen is <sup>18</sup>F.

6. (Original) The analogue of claim 4, wherein the halogen is <sup>123</sup>I.

7-8. (Cancelled).

9. (Original) The analogue of claim 1, wherein the analogue is selected from the group consisting of: [<sup>18</sup>F] labeled L,D-2-amino-3-(2-fluoromethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoromethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoromethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(2-fluoroethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoroethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoroethyl-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoromethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoromethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(5-fluoromethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(6-fluoromethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-

amino-3-(3-fluoroethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoroethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(5-fluoroethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(6-fluoroethyl-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(2-fluoromethyl-4-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(5-fluoromethyl-3-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(6-fluoromethyl-3-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(2-fluoroethyl-4-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(5-fluoroethyl-3-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(6-fluoroethyl-3-hydroxy-phenyl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoromethyl-5-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoroethyl-5-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoromethyl-6-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoromethyl-6-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(3-fluoroethyl-6-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labeled L,D-2-amino-3-(4-fluoroethyl-6-hydroxy-pyridin-2-yl)-propionic acid; [<sup>18</sup>F] labelled alanine; [<sup>18</sup>F] labelled valine; [<sup>18</sup>F] labelled leucine; [<sup>18</sup>F] labelled isoleucine; and [<sup>18</sup>F] labelled methionine.

10. (Original) A pharmaceutical composition comprising the analogue of claim 1 and at least one of an excipient, carrier and diluent.

11. (Original) The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is used as a tracer in at least one of Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (MRI).

12-24. (Cancelled).